View Post

Digital breast tomosynthesis reduces rate of interval cancers

In Clinical Studies News by Barbara Jacoby

Source: Radiological Society of North America From: eurekalert.org Screening with digital breast tomosynthesis (DBT) reduces the rate of interval breast cancers compared to screening with digital mammography, according to a study published in Radiology. The study adds to a growing body of evidence supporting DBT as a breast cancer screening tool with important advantages over mammography. DBT works by capturing …

View Post

Longer Follow-Up Is Imperative With Adjuvant CDK4/6 Inhibitors in ER+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Courtney Marabella From: onclive.com Optimal patient selection and duration of therapy are the 2 biggest areas to tackle regarding CDK4/6 inhibition in the adjuvant setting of estrogen receptor (ER)–positive breast cancer, explained Ruth O’Regan, MBBCh, BAO. Longer follow-up from the PENELOPE-B (NCT01864746), PALLAS (NCT02513394), and monarchE (NCT03155997) trials, and data from the ongoing NATALEE (NCT03701334) study, will likely assist …

View Post

Meisel on Managing Toxicities With T-DM1 in HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Courtney Marabella From: onclive.com Data from the pivotal phase 3 KATHERINE (NCT01772472) has led to the addition of ado-trastuzumab emtansine (T-DM1; Kadcyla) to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it, according to Jane L. Meisel, MD. The phase 3 KATHERINE trial …

View Post

MINDACT points to differential breast cancer chemotherapy benefit by age

In Clinical Studies News by Barbara Jacoby

By: hreeya Nanda From: medwirenews.com Exploratory data from the MINDACT trial suggest that women older than 50 years who have high clinical risk but low genomic risk according to the 70-gene MammaPrint signature may be able to forgo adjuvant chemotherapy for early-stage breast cancer. By contrast, “in younger women, a potentially clinically relevant chemotherapy benefit of about 5 percentage points is …

View Post

Fast breast MRI ready for clinical use following shorter read times, accurate cancer detection

In Clinical Studies News by Barbara Jacoby

By: Matt O’Connor From: healthimaging.com In high-risk women, abbreviated breast MRI protocols require shorter interpretation times while maintaining similar cancer detection rates compared to full-sequence magnetic resonance imaging, according to a recent analysis. Standard MRI beats out most other modalities at detecting breast cancer, yet its nearly one-hour imaging time can make exams difficult for many patients, experts wrote in …

View Post

Potential new treatment strategy for breast cancer cells that have spread to the brain

In Clinical Studies News by Barbara Jacoby

Source: Massachusetts General Hospital From: eurekalert.org New research reveals that when breast cancer cells spread to the brain, they must boost production of fatty acids, the building blocks of fat, in order to survive there. The work, which is published in Nature Cancer and was led by investigators at Massachusetts General Hospital (MGH) and the Koch Institute of the Massachusetts …

View Post

FDA Approval Sought for F-627 for Chemotherapy-Induced Neutropenia in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com A biologics license application has been submitted to the FDA for the approval of F-627 as a treatment option for patients with breast cancer who have chemotherapy-induced neutropenia. A biologics license application has been submitted to the FDA for the approval of F-627 (Ryzneuta; formerly efbemalenograstim alpha) as a treatment option for patients with breast …

View Post

New Research Indicates ProFound AI May Reduce Interval Breast Cancer Rates

In Clinical Studies News by Barbara Jacoby

Source: iCAD Inc. From: yahoo.com Retrospective analysis published in Journal of Medical Screening suggests that ProFound AI for 2D Mammography could have helped detect 48% of interval cancers and 93% of subgroups that include false-negatives and minimal sign lesions iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ProFound® AI …

View Post

New drug could help in breast cancer fight, Scottish research finds

In Clinical Studies News by Barbara Jacoby

By: Craig Cairns From: thenational.scot A PROTEIN which helps breast cancer tumours survive could be targeted with a new type of drug that is already being tested for other cancers, research suggests The protein, known as MCL-1, helps breast cancer cells survive by hindering their natural ability to die. This process, called apoptosis, is the body’s way of getting rid …

View Post

Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics

In Clinical Studies News by Barbara Jacoby

Source: Newsfile Corp. From: finance.yahoo.com – The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment – Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 months Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) (“Portage” or the “Company”) a clinical stage immuno-oncology company accelerating research and …